139 related articles for article (PubMed ID: 9403781)
1. Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats.
Cox EH; Van Hemert JG; Tukker EJ; Danhof M
J Pharmacol Toxicol Methods; 1997 Oct; 38(2):99-108. PubMed ID: 9403781
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation.
Cox EH; Kuipers JA; Danhof M
Br J Pharmacol; 1998 Aug; 124(7):1534-40. PubMed ID: 9723968
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat.
Mandema JW; Wada DR
J Pharmacol Exp Ther; 1995 Dec; 275(3):1185-94. PubMed ID: 8531080
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor.
Cox EH; Kerbusch T; Van der Graaf PH; Danhof M
J Pharmacol Exp Ther; 1998 Mar; 284(3):1095-103. PubMed ID: 9495871
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic modelling of the analgesic effect of alfentanil in the rat using tooth pulp evoked potentials.
Cox EH; Langemeijer MW; Danhof M
J Pharmacol Toxicol Methods; 1998 Feb; 39(1):19-27. PubMed ID: 9596144
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration.
Mandema JW; Tukker E; Danhof M
Br J Pharmacol; 1991 Mar; 102(3):663-8. PubMed ID: 1364836
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic analysis of the EEG effect of alfentanil in rats following beta-funaltrexamine-induced mu-opioid receptor "knockdown" in vivo.
Garrido M; Gubbens-Stibbe J; Tukker E; Cox E; von Frijtag J; Künzel D; IJzerman A; Danhof M; van der Graaf PH
Pharm Res; 2000 Jun; 17(6):653-9. PubMed ID: 10955836
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics.
Groenendaal D; Freijer J; Rosier A; de Mik D; Nicholls G; Hersey A; Ayrton AD; Danhof M; de Lange EC
Eur J Pharm Sci; 2008 Jul; 34(2-3):149-63. PubMed ID: 18467078
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients.
Frenkel C; Schuttler J; Ihmsen H; Heye H; Rommelsheim K
Intensive Care Med; 1995 Dec; 21(12):981-8. PubMed ID: 8750122
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of alfentanil.
Bouillon T; Schmidt C; Garstka G; Heimbach D; Stafforst D; Schwilden H; Hoeft A
Anesthesiology; 1999 Jul; 91(1):144-55. PubMed ID: 10422940
[TBL] [Abstract][Full Text] [Related]
11. Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers.
Egan TD; Minto CF; Hermann DJ; Barr J; Muir KT; Shafer SL
Anesthesiology; 1996 Apr; 84(4):821-33. PubMed ID: 8638836
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil.
Lemmens HJ; Dyck JB; Shafer SL; Stanski DR
Clin Pharmacol Ther; 1994 Sep; 56(3):261-71. PubMed ID: 7924121
[TBL] [Abstract][Full Text] [Related]
13. Measured context-sensitive half-times of remifentanil and alfentanil.
Kapila A; Glass PS; Jacobs JR; Muir KT; Hermann DJ; Shiraishi M; Howell S; Smith RL
Anesthesiology; 1995 Nov; 83(5):968-75. PubMed ID: 7486182
[TBL] [Abstract][Full Text] [Related]
14. [Analgo-sedation in intensive care: a quantitative, EEG-based trial with propofol 1% and 2%].
Albrecht S; Ihmsen H; Suchodolski K; Frenkel C; Schüttler J
Anaesthesist; 1999 Nov; 48(11):794-801. PubMed ID: 10631438
[TBL] [Abstract][Full Text] [Related]
15. Validation of the alfentanil canonical univariate parameter as a measure of opioid effect on the electroencephalogram.
Gambús PL; Gregg KM; Shafer SL
Anesthesiology; 1995 Oct; 83(4):747-56. PubMed ID: 7574054
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij rats.
Hovinga S; Stijnen AM; Langemeijer MW; Mandema JW; van Bezooijen CF; Danhof M
Br J Pharmacol; 1992 Sep; 107(1):171-7. PubMed ID: 1422570
[TBL] [Abstract][Full Text] [Related]
17. Application of a combined "effect compartment/indirect response model" to the central nervous system effects of tiagabine in the rat.
Cleton A; de Greef HJ; Edelbroek PM; Voskuyl RA; Danhof M
J Pharmacokinet Biopharm; 1999 Jun; 27(3):301-23. PubMed ID: 10728492
[TBL] [Abstract][Full Text] [Related]
18. Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship.
Mandema JW; Kuck MT; Danhof M
Br J Pharmacol; 1992 Jan; 105(1):164-70. PubMed ID: 1350744
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of heptabarbital using aperiodic EEG analysis.
Mandema JW; Danhof M
J Pharmacokinet Biopharm; 1990 Oct; 18(5):459-81. PubMed ID: 1979991
[TBL] [Abstract][Full Text] [Related]
20. Influence of Escherichia coli endotoxin on the pharmacokinetics and respiratory depressant effect of alfentanil in rabbits.
Björkman S; Redke F
J Pharm Sci; 1996 Jul; 85(7):680-4. PubMed ID: 8818989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
